“Dendreon announced a much-anticipated facility shut-down, although the Street was not expecting the closing of the company’s largest manufacturing facility,” said Barclays analyst Ying Huang in a note, halving the price target on the …
and whose disease has spread to the lungs or the brain. Previously, patients whose cancer spread to the brain or lungs were not covered. Patients whose disease has spread to the liver still are not covered. Dendreon's shares closed 3.9 …
On April 3, Seattle’s Dendreon Corp. said it had raised $46 million by selling 8 million shares and an additional 8 million warrants of its stock to an unnamed institutional investor. The deal surprised the company’s watchers, both because …
Cancer drug developer Dendreon announced Q4 revenue early. And revenue was good. Gross product revenue jumped 230% year-over-year to $82 million. This also represents a 25% increase from Q3. "We are pleased with the progress …
Last Thursday Dendreon’s much-debated prostate cancer therapy, Provenge, was approved. And company insiders were able to celebrate properly, thanks to a flurry of subsequent stock sales that netted them millions, the WSJ reports. …
Yet on a morning that saw the company disclose nothing remotely controversial during its quarterly conference call, BioCryst’s stock fell about 15 percent. Dendreon stock plunged more than 60 percent on the results. The company said …
The plaintiff alleges that certain defendants knew the rosy statements were "completely false" and unlike defendants, …
DNDN) from $40 to $50. The firm has a BUY rating on the stock. They believe that there is a likelihood that Dendreon's (DNDN) prostrate cancer drug Provenge will be approved by the FDA. During today's trading session, DNDN shares …
And to others, Dendreon is a company that is deeply misunderstood, and whose true value has yet to be realized. Since the company went public over a decade ago, its stock has been a battlefield between these two opposing forces. …